Welcome to our dedicated page for Senti Bioscience news (Ticker: SNTI), a resource for investors and traders seeking the latest updates and insights on Senti Bioscience stock.
Senti Biosciences, Inc. (Senti Bio) (NASDAQ: SNTI) is a clinical-stage biotechnology company developing cell and gene therapies that incorporate engineered Gene Circuits. This news page aggregates company announcements, scientific updates, and corporate disclosures so readers can follow how Senti Bio advances its Gene Circuit platform and clinical programs over time.
A major focus of Senti Bio’s news flow is SENTI-202, its first-in-class Logic Gated off-the-shelf CAR-NK cell therapy product candidate. Company releases describe ongoing Phase 1 clinical evaluation of SENTI-202 in adults with relapsed or refractory CD33 and/or FLT3 expressing hematologic malignancies, including acute myeloid leukemia and myelodysplastic syndrome. Updates have highlighted clinical and pharmacodynamic data, presentations at the American Society of Hematology (ASH) Annual Meeting, and FDA designations such as Orphan Drug Designation and Regenerative Medicine Advanced Therapy (RMAT) designation.
Visitors can also expect news on Senti Bio’s participation in investor and scientific conferences, quarterly financial result announcements, and communications about its broader Gene Circuit platform. These items provide context on how the company positions its synthetic biology approach, preclinical work in NK and T cells, and efforts to explore Gene Circuits in other modalities and disease areas through partnerships.
For investors and observers tracking SNTI, this page offers a centralized view of press releases and related information, from clinical data readouts and regulatory milestones to corporate presentations. Checking this feed periodically can help users understand the evolution of Senti Bio’s pipeline and its activities within the cell and gene therapy landscape.
Senti Biosciences (Nasdaq: SNTI) has secured an $8 million grant from the California Institute for Regenerative Medicines (CIRM) to support the clinical development of SENTI-202. This investigational cell therapy is a potential first-in-class Logic Gated off-the-shelf CAR-NK treatment for relapsed/refractory hematologic malignancies, including acute myeloid leukemia (AML). The Phase 1 clinical trial (NCT06325748) is currently enrolling adult patients with r/r CD33 and/or FLT3 expressing hematologic malignancies in the United States and Australia. Senti Bio expects to receive the first tranche of the grant in August 2024 and anticipates initial efficacy data by year-end 2024, with durability data following in 2025.
Senti Biosciences (Nasdaq: SNTI) has announced a 1-for-10 reverse stock split effective July 17, 2024, at 11:59 p.m. EDT. Trading on a split-adjusted basis will begin on July 18, 2024. This move will reduce outstanding shares from approximately 45.8 million to 4.6 million. The reverse split aims to address Nasdaq's minimum bid price requirement of $1.00 per share, which SNTI has not met since August 2023. Senti Bio has until August 5, 2024, to regain compliance by maintaining a closing bid price of at least $1.00 for 10 consecutive business days. The company believes this action will increase its stock price and resolve the compliance issue.
Senti Biosciences (Nasdaq: SNTI) has been awarded an $8 million grant by the California Institute for Regenerative Medicines (CIRM) for the clinical development of SENTI-202, a potential first-in-class Logic Gated CAR-NK cell therapy. This therapy targets relapsed/refractory hematologic malignancies, including acute myeloid leukemia (AML). The ongoing Phase 1 trial is enrolling adult patients in the US and Australia, evaluating two dosing levels. Initial efficacy data is expected by the end of 2024, with durability data following in 2025.
Senti Bio has dosed the first patient in the Phase 1 clinical trial of SENTI-202, a Logic Gated CAR-NK cell therapy for relapsed or refractory hematologic malignancies, including AML. The therapy targets CD33 and FLT3 expressing cells while sparing healthy bone marrow. Initial efficacy data is expected by 2024 end, with durability data in 2025. The trial is enrolling adult patients in the US and Australia, evaluating two dose levels. Senti Bio aims to redefine AML care with SENTI-202.
Senti Bio reported operational updates and financial results for the first quarter of 2024, highlighting the progress in their Phase 1 clinical trial of SENTI-202 for AML and SENTI-301A for HCC in collaboration with Celest. They also presented at ASGCT 2024 Annual Meeting on platform advancements. The company reported cash and cash equivalents of $23.7 million, with R&D expenses at $8.8 million and net loss of $12.1 million for the quarter. Senti Bio plans to participate in the BIO International Convention 2024 in San Diego, CA.
Senti Bio announced the publication of preclinical data on SENTI-202, a logic-gated CAR-NK cell therapy for AML, showing improved treatment outcomes and reduced toxicity. The data supports the upcoming Phase 1 clinical trial, with patient dosing expected in Q2 2024.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
FAQ
What is the current stock price of Senti Bioscience (SNTI)?
What is the market cap of Senti Bioscience (SNTI)?
